VT 1161

Drug Profile

VT 1161

Alternative Names: VT-1161

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Viamet Pharmaceuticals
  • Class Antifungals; Azoles; Small molecules
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Vulvovaginal candidiasis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Onychomycosis; Vulvovaginal candidiasis
  • No development reported Tinea pedis

Most Recent Events

  • 06 Jan 2017 Efficacy and adverse event data from the phase II RENOVATE trial in Onychomycosis, which met the primary endpoint, released by Viamet
  • 06 Jan 2017 Updated efficacy and safety data from a phase IIb REVIVE trial in Vulvovaginal candidiasis released by Viamet Pharmaceuticals
  • 14 Oct 2016 VT 1161 receives Fast Track designation for Vulvovaginal candidiasis [PO,Tablet] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top